Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

NEWARK, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- NRSInsights, a provider of sales data and analytics drawn from retail ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

The Company granted options to purchase 250,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $4.46, which was the closing ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.